SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Furosemide Injection Formulation

Version 3.6
Revision Date: 27.08.2021
SDS Number: 657929-00013
Date of last issue: 09.04.2021
Date of first issue: 03.05.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name: Furosemide Injection Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture: Veterinary product

1.3 Details of the supplier of the safety data sheet

Company: MSD
Kilsheelan
Clonmel Tipperary, IE

Telephone: 353-51-601000

E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)
Specific target organ toxicity - repeated exposure, Category 2: H373: May cause damage to organs through prolonged or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms: 🔴

Signal word: Warning

Hazard statements: H373 May cause damage to organs through prolonged or repeated exposure.

Precautionary statements: Response:
P314 Get medical advice/attention if you feel unwell.

Hazardous components which must be listed on the label:
Furosemide
2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furosemide</td>
<td>54-31-9</td>
<td>200-203-6</td>
<td></td>
<td></td>
<td>STOT RE 1; H372 (Kidney, Liver)</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
</tbody>
</table>
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Nitrogen oxides (NOx)
- Carbon oxides
- Sulphur oxides
- Chlorine compounds

5.3 Advice for firefighters

Special protective equipment for firefighters:
In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Furosemide Injection Formulation

Version 3.6	Revision Date: 27.08.2021	SDS Number: 657929-00013	Date of last issue: 09.04.2021

6.2 Environmental precautions
Environmental precautions:
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up:
Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling
Technical measures:
See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
Use only with adequate ventilation.

Advice on safe handling:
Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types:
- Strong oxidizing agents
- Organic peroxides
- Explosives
- Gases

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

**Occupational Exposure Limits**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furosemide</td>
<td>54-31-9</td>
<td>TWA</td>
<td>200 µg/m³</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>OEB 2 (&gt;=100 - 1000 µg/m³)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

**Engineering measures**

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

**Personal protective equipment**

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection: Chemical-resistant gloves

Skin and body protection: Work uniform or laboratory coat.

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143

Filter type: Particulates type (P)
SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state</td>
<td>Aqueous solution</td>
</tr>
<tr>
<td>Colour</td>
<td>yellow</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling</td>
<td>No data available</td>
</tr>
<tr>
<td>range</td>
<td></td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper</td>
<td>No data available</td>
</tr>
<tr>
<td>flammability limit</td>
<td></td>
</tr>
<tr>
<td>Lower explosion limit / Lower</td>
<td>No data available</td>
</tr>
<tr>
<td>flammability limit</td>
<td></td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td></td>
</tr>
<tr>
<td>Water solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>No data available</td>
</tr>
<tr>
<td>Particle characteristics</td>
<td></td>
</tr>
<tr>
<td>Particle size</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Explosives</td>
<td>Not explosive</td>
</tr>
</tbody>
</table>
Furosemide Injection Formulation

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: None known.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

Furosemide:
Acute oral toxicity: LD50 (Rat): 2,600 mg/kg
LD50 (Dog): 2,000 mg/kg
LD50 (Rabbit): 800 mg/kg

Acute toxicity (other routes of administration): LD0 (Humans): 6 - 29 mg/kg
Application Route: Intravenous
LD50 (Rat): 800 mg/kg
Application Route: Intravenous
Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Components:

Furosemide:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: mouse lymphoma cells
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: mammalian liver cells
Result: negative

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: positive

Test Type: In vitro sister chromatid exchange assay in mammalian cells
Test system: Chinese hamster cells
Result: negative

Genotoxicity in vivo:
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Chinese hamster
Application Route: Ingestion
Result: negative

Carcinogenicity
Not classified based on available information.
Furosemide Injection Formulation

Components:

Furosemide:
Species: Rat
Application Route: Ingestion
Exposure time: 104 weeks
LOAEL: 16 mg/kg body weight
Result: equivocal

Species: Mouse
Application Route: Ingestion
Exposure time: 2 Years
LOAEL: 91 mg/kg body weight
Result: positive

Reproductive toxicity
Not classified based on available information.

Components:

Furosemide:
Effects on fertility: Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
General Toxicity - Parent: NOAEL: 90 mg/kg body weight
Result: No effects on reproduction parameters

Test Type: One-generation reproduction toxicity study
Species: Mouse
Application Route: Ingestion
General Toxicity - Parent: NOAEL: 200 mg/kg body weight
Result: No effects on reproduction parameters

Effects on foetal development: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 50 mg/kg body weight
Developmental Toxicity: NOAEL: 300 mg/kg body weight
Result: No embryotoxic effects, No teratogenic effects

Test Type: Fertility/early embryonic development
Species: Mouse
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 25 mg/kg body weight
Result: Maternal toxicity observed., Fetal effects

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight
Developmental Toxicity: LOAEL: 12.5 mg/kg body weight
Result: Maternal toxicity observed., Reduced number of viable fetuses
Furosemide Injection Formulation

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 15 mg/kg body weight
Result: Maternal toxicity observed., No effects on foetal development

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:
Furosemide:
Exposure routes: Ingestion
Target Organs: Kidney
Assessment: Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

Repeated dose toxicity
Components:
Furosemide:
Species: Dog
NOAEL: 4 mg/kg
LOAEL: 8 mg/kg
Application Route: Ingestion
Exposure time: 12 Months
Target Organs: Kidney
Symptoms: Blood disorders
Remarks: Significant toxicity observed in testing

Aspiration toxicity
Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
## Experience with human exposure

**Components:**

**Furosemide:**
- **Inhalation:** Remarks: May be harmful if inhaled.
- **Skin contact:** Remarks: May irritate skin.
- **Eye contact:** Remarks: May cause eye irritation.
- **Ingestion:** Symptoms: Kidney disorders, Headache, electrolyte imbalance, dry mouth, hearing loss, Irregular cardiac activity, Gastrointestinal disturbance, hypotension

### SECTION 12: Ecological information

#### 12.1 Toxicity

**Components:**

**Furosemide:**
- **Toxicity to fish:** LC50: 500 mg/l
  Exposure time: 96 h

#### 12.2 Persistence and degradability

No data available

#### 12.3 Bioaccumulative potential

**Components:**

**Furosemide:**
- **Partition coefficient:** n-octanol/water: log Pow: 2.03

#### 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

**Product:**
- **Assessment:** This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

#### 12.6 Endocrine disrupting properties

**Product:**
- **Assessment:** The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
SECTION 3: Chemical identification

3.1.1 Identity of the manufacturer/supplier of the substance or mixture

MSD

3.1.2 Identification of the substance or mixture

SAFETY DATA SHEET
Furosemide Injection Formulation

3.1.3态s of the substance or mixture

Section 1: Identification of the substance or mixture

3.1.4 Chemical identification

SAFETY DATA SHEET
Furosemide Injection Formulation

3.1.5 GHS classification of the substance or mixture

Section 2: hazards identification

3.1.6 Precautionary statements

SAFETY DATA SHEET
Furosemide Injection Formulation

3.1.7.1 First-aid measures

SAFETY DATA SHEET
Furosemide Injection Formulation

3.2 Hazard classification and packaging information

SAFETY DATA SHEET
Furosemide Injection Formulation

3.3 Composition information

SAFETY DATA SHEET
Furosemide Injection Formulation

3.3.1 Substances

SAFETY DATA SHEET
Furosemide Injection Formulation

3.3.2 Ingredients identified by their function

SAFETY DATA SHEET
Furosemide Injection Formulation

3.3.3 Other information

SAFETY DATA SHEET
Furosemide Injection Formulation

3.4.1 Environmental information

SAFETY DATA SHEET
Furosemide Injection Formulation

3.4.2 Restrictions on the use of the substance or mixture

SAFETY DATA SHEET
Furosemide Injection Formulation

3.4.3 Precautions for safe storage, handling, transport and use

SAFETY DATA SHEET
Furosemide Injection Formulation

3.4.4.1 Transport information

SAFETY DATA SHEET
Furosemide Injection Formulation

3.4.4.2 Regulatory information

SAFETY DATA SHEET
Furosemide Injection Formulation

SECTION 8: Exports and imports

SAFETY DATA SHEET
Furosemide Injection Formulation

SECTION 15: Regulatory information

SAFETY DATA SHEET
Furosemide Injection Formulation

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

SAFETY DATA SHEET
Furosemide Injection Formulation

15.1.1 REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII)

SAFETY DATA SHEET
Furosemide Injection Formulation

15.1.2 REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).

SAFETY DATA SHEET
Furosemide Injection Formulation

15.1.3 Regulation (EC) No 1005/2009 on substances that deplete the ozone layer

SAFETY DATA SHEET
Furosemide Injection Formulation

15.1.4 Regulation (EU) 2019/1021 on persistent organic pollutants (recast)

SAFETY DATA SHEET
Furosemide Injection Formulation

15.1.5 Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import

SAFETY DATA SHEET
Furosemide Injection Formulation

12 / 14
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Furosemide Injection Formulation

Version 3.6  Revision Date: 27.08.2021  SDS Number: 657929-00013  Date of last issue: 09.04.2021
Date of first issue: 03.05.2016

of dangerous chemicals
REACH - List of substances subject to authorisation : Not applicable
(Annex XIV)
major-accident hazards involving dangerous substances.
Not applicable

Other regulations:
Take note of Directive 94/33/EC on the protection of young people at work or stricter national
regulations, where applicable.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H372 : Causes damage to organs through prolonged or repeated exposure.

Full text of other abbreviations
STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland
Waterways; ADR - European Agreement concerning the International Carriage of Dangerous
Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for
the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation;
Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -
Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada);
ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -
Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -
Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - Interna-
tional Air Transport Association; IBC - International Code for the Construction and Equipment of
Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO -
International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in
China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organiza-
tion; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Stand-
ardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a
test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -
International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Speci-
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Furosemide Injection Formulation

Version: 3.6  Revision Date: 27.08.2021  SDS Number: 657929-00013  Date of last issue: 09.04.2021
Date of first issue: 03.05.2016

Further information
Sources of key data used to compile the Safety Data Sheet:

Classification of the mixture:
STOT RE 2 H373

Classification procedure:
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN